Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pazopanib vs. Placebo in Metastatic RCC Following Metastasectomy
NCT01575548Phase 3Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Aug 2012
- Primary completion
- Jul 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in renal cell carcinoma (RCC) comparing Arm A (Pazopanib) with Arm B (Placebo) (2 arms). Primary endpoint: Disease-free Survival up to 6 years. Started Aug 2012; status: active, not recruiting.
02
Drugs
pazopanib
03
Conditions
renal cell carcinoma (RCC)
Beyond the preview
Go deeper on NCT01575548.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01575548.